UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies

European journal of neurology, 2020-03, Vol.27 (3), p.542-549

2020

Volltextzugriff (PDF)

A Review of Spontaneous Intracranial Hypotension

Current neurology and neuroscience reports, 2019-05, Vol.19 (5), p.22-6, Article 22

2019

Volltextzugriff (PDF)

The Effect of Onabotulinum Toxin A on Chronic Post-Traumatic Headaches Refractory to Standard Preventative Therapy (P03.223)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P03-P03.223

2012

Volltextzugriff (PDF)

Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications

Journal of the neurological sciences, 2019-10, Vol.405, p.45-46

2019

Volltextzugriff (PDF)

PND102 CORRELATION ANALYSIS OF THE CHANGE IN THREE SF-36 DOMAINS WITH CHANGE IN PATIENT-IDENTIFIED MOST BOTHERSOME SYMPTOM AND MONTHLY MIGRAINE DAYS IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS OF THE PROMISE-2 STUDY

Value in health, 2020-05, Vol.23, p.S279-S279

2020

Volltextzugriff (PDF)

Reversion from chronic to episodic migraine in patients with inadequate response to 2-4 classes of migraine preventive treatments in the focus phase 3b study

Journal of the neurological sciences, 2019-10, Vol.405, p.65-65

2019

Volltextzugriff (PDF)

Diagnose and Adios: Practical Tips for the Ongoing Evaluation and Care of TAC Patients Taking Indomethacin

Current pain and headache reports, 2015-02, Vol.19 (2), p.470-470, Article 470

2015

Volltextzugriff (PDF)

P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study

Canadian journal of neurological sciences, 2021-11, Vol.48 (s3), p.S27-S28

2021

Volltextzugriff (PDF)

P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II

Canadian journal of neurological sciences, 2019-06, Vol.46 (s1), p.S16-S16

2019

Volltextzugriff (PDF)

A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I

Canadian journal of neurological sciences, 2019-06, Vol.46 (s1), p.S9-S10

2019

Volltextzugriff (PDF)

Atogepant for the Preventive Treatment of Migraine

The New England journal of medicine, 2021-08, Vol.385 (8), p.695-706

2021

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Lancet neurology, 2020-09, Vol.19 (9), p.727-737

2020

Volltextzugriff (PDF)

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Journal of headache and pain, 2020-10, Vol.21 (1), p.123-123, Article 123

2020

Volltextzugriff (PDF)

Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine (1227)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update

Headache, 2024-04, Vol.64 (4), p.333-341

2024

Volltextzugriff (PDF)

Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR)

Journal of headache and pain, 2024-04, Vol.25 (1), p.55-55, Article 55

2024

Volltextzugriff (PDF)

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials

Journal of headache and pain, 2024-03, Vol.25 (1), p.35-35, Article 35

2024

Volltextzugriff (PDF)

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review

Neurology, 2022-11, Vol.99 (19), p.841-853

2022

Volltextzugriff (PDF)

Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure

Journal of headache and pain, 2022-12, Vol.23 (1), p.148-148, Article 148

2022

Volltextzugriff (PDF)

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

CNS drugs, 2024-10

2024

Volltextzugriff (PDF)

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-09, Vol.402 (10404), p.775-785

2023

Volltextzugriff (PDF)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Cephalalgia, 2022-01, Vol.42 (1), p.3-11

2022

Volltextzugriff (PDF)

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

Headache, 2021-10, Vol.61 (9), p.1411-1420

2021

Volltextzugriff (PDF)

Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency

Disease models & mechanisms, 2023-06, Vol.16 (6)

2023

Volltextzugriff (PDF)

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial (S47.002)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(49)

Sprache

Englisch
(46)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies

A Review of Spontaneous Intracranial Hypotension

The Effect of Onabotulinum Toxin A on Chronic Post-Traumatic Headaches Refractory to Standard Preventative Therapy (P03.223)

Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications

PND102 CORRELATION ANALYSIS OF THE CHANGE IN THREE SF-36 DOMAINS WITH CHANGE IN PATIENT-IDENTIFIED MOST BOTHERSOME SYMPTOM AND MONTHLY MIGRAINE DAYS IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS OF THE PROMISE-2 STUDY

Reversion from chronic to episodic migraine in patients with inadequate response to 2-4 classes of migraine preventive treatments in the focus phase 3b study

Diagnose and Adios: Practical Tips for the Ongoing Evaluation and Care of TAC Patients Taking Indomethacin

P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study

P.010 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE II

A.07 Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: a single-attack phase 3 study, ACHIEVE I

Atogepant for the Preventive Treatment of Migraine

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine (1227)

Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update

Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR)

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review

Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data

Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial (S47.002)

Suchergebnisse filtern